Kidney-specific tumor vaccine directed against kidney tumor antigen G-250
AssigneeThe Regents of the University of California
InventorsArie Belldegrun, Cho-Lea Tso
Life of this patent
Estimating the term…
Abstract
This invention provides an anti-cancer immunogenic agent(s) (e.g. vaccines) that elicit an immune response specifically directed against renal cell cancers expressing a G250 antigenic marker. Preferred immunogenic agents comprise a chimeric molecule comprising a kidney cancer specific antigen (G250) attached to a granulocyte-macrophage colony stimulating factor (GM-CSF). The agents are useful in a wide variety of treatment modalities including, but not limited to protein vaccination, DNA vaccination, and adoptive immunotherapy.
Claims85
A construct comprising a G250 kidney cancer specific antigen attached to a granulocyte macrophage colony stimulating factor (GM-CSF).
A composition comprising a G250 kidney cancer specific antigen attached to a granulocyte macrophage colony stimulating factor (GM-CSF), and a pharmaceutically acceptable diluent or excipient.
A nucleic acid encoding a fusion protein comprising a G250 kidney cancer specific antigen attached to a granulocyte macrophage colony stimulating factor (GM-CSF).
A method of inducing an immune response against the G250 kidney-specific antigen or a cell displaying the G250 kidney-specific antigen, said method comprising:
- activating a cell of the immune system with a construct comprising a kidney cancer specific antigen (G250) attached to a granulocyte macrophage colony stimulating factor (GM-CSF) whereby said activating provides an immune response directed against the G250 antigen.
The method of claim 57, wherein the activated cell is a cytotoxic T-lymphocyte (CTL).
A method of inhibiting the proliferation or growth of a transformed kidney cell, said method comprising:
- activating a cell of the immune system with a construct comprising a kidney cancer specific antigen (G250) attached to a granulocyte macrophage colony stimulating factor (GM-CSF) whereby said activating provides an immune response directed against the G250 antigen and said immune response inhibits the growth or proliferation of a transformed kidney cell.
A method of inhibiting the proliferation or growth of a transformed renal cell that bears a G250 antigen, said method comprising:
- removing an immune cell from a mammalian host;
- activating said immune cell by contacting said cell with a protein comprising a renal cell carcinoma specific antigen (G250) attached to a granulocyte macrophage colony stimulating factor (GM-CSF) or a fragment thereof;
- optionally expanding the activated cell;
- and
- infusing the activated cell into an organism containing a transformed renal cell bearing a G250 antigen.
A method of treating an individual having a renal cell cancer, said method comprising:
- (a) sensitizing antigen presenting cells in vitro with a sensitizing-effective amount of a chimeric fusion protein comprising a renal cell carcinoma specific antigen (G250) attached to a granulocyte macrophage colony stimulating factor (GM-CSF);
- and
- (b) administering to an individual having said renal cell cancer or metastasis a therapeutically effective amount of the sensitized antigen presenting cells.
Dependencies are inferred from the claim text.